BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 25645699)

  • 1. Rescue of gene-expression changes in an induced mouse model of spinal muscular atrophy by an antisense oligonucleotide that promotes inclusion of SMN2 exon 7.
    Staropoli JF; Li H; Chun SJ; Allaire N; Cullen P; Thai A; Fleet CM; Hua Y; Bennett CF; Krainer AR; Kerr D; McCampbell A; Rigo F; Carulli JP
    Genomics; 2015 Apr; 105(4):220-8. PubMed ID: 25645699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. hnRNP M facilitates exon 7 inclusion of SMN2 pre-mRNA in spinal muscular atrophy by targeting an enhancer on exon 7.
    Cho S; Moon H; Loh TJ; Oh HK; Cho S; Choy HE; Song WK; Chun JS; Zheng X; Shen H
    Biochim Biophys Acta; 2014; 1839(4):306-15. PubMed ID: 24533984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape.
    Wood MJA; Talbot K; Bowerman M
    Hum Mol Genet; 2017 Oct; 26(R2):R151-R159. PubMed ID: 28977438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model.
    Hua Y; Sahashi K; Hung G; Rigo F; Passini MA; Bennett CF; Krainer AR
    Genes Dev; 2010 Aug; 24(15):1634-44. PubMed ID: 20624852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy.
    Williams JH; Schray RC; Patterson CA; Ayitey SO; Tallent MK; Lutz GJ
    J Neurosci; 2009 Jun; 29(24):7633-8. PubMed ID: 19535574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Securinine enhances SMN2 exon 7 inclusion in spinal muscular atrophy cells.
    Chen YC; Chang JG; Liu TY; Jong YJ; Cheng WL; Yuo CY
    Biomed Pharmacother; 2017 Apr; 88():708-714. PubMed ID: 28152480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model.
    Hua Y; Sahashi K; Rigo F; Hung G; Horev G; Bennett CF; Krainer AR
    Nature; 2011 Oct; 478(7367):123-6. PubMed ID: 21979052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
    Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C
    J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and characterization of an SMN2-based intermediate mouse model of Spinal Muscular Atrophy.
    Cobb MS; Rose FF; Rindt H; Glascock JJ; Shababi M; Miller MR; Osman EY; Yen PF; Garcia ML; Martin BR; Wetz MJ; Mazzasette C; Feng Z; Ko CP; Lorson CL
    Hum Mol Genet; 2013 May; 22(9):1843-55. PubMed ID: 23390132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of SMN trans-splicing and a neurotrophic factor increases the life span and body mass in a severe model of spinal muscular atrophy.
    Shababi M; Glascock J; Lorson CL
    Hum Gene Ther; 2011 Feb; 22(2):135-44. PubMed ID: 20804424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of combined systemic and local morpholino treatment on the spinal muscular atrophy Δ7 mouse model phenotype.
    Nizzardo M; Simone C; Salani S; Ruepp MD; Rizzo F; Ruggieri M; Zanetta C; Brajkovic S; Moulton HM; Müehlemann O; Bresolin N; Comi GP; Corti S
    Clin Ther; 2014 Mar; 36(3):340-56.e5. PubMed ID: 24636820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Counteracting chromatin effects of a splicing-correcting antisense oligonucleotide improves its therapeutic efficacy in spinal muscular atrophy.
    Marasco LE; Dujardin G; Sousa-Luís R; Liu YH; Stigliano JN; Nomakuchi T; Proudfoot NJ; Krainer AR; Kornblihtt AR
    Cell; 2022 Jun; 185(12):2057-2070.e15. PubMed ID: 35688133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophy.
    Mitrpant C; Porensky P; Zhou H; Price L; Muntoni F; Fletcher S; Wilton SD; Burghes AH
    PLoS One; 2013; 8(4):e62114. PubMed ID: 23630626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normalization of Patient-Identified Plasma Biomarkers in SMNΔ7 Mice following Postnatal SMN Restoration.
    Arnold WD; Duque S; Iyer CC; Zaworski P; McGovern VL; Taylor SJ; von Herrmann KM; Kobayashi DT; Chen KS; Kolb SJ; Paushkin SV; Burghes AH
    PLoS One; 2016; 11(12):e0167077. PubMed ID: 27907033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy.
    Riessland M; Ackermann B; Förster A; Jakubik M; Hauke J; Garbes L; Fritzsche I; Mende Y; Blumcke I; Hahnen E; Wirth B
    Hum Mol Genet; 2010 Apr; 19(8):1492-506. PubMed ID: 20097677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNA-based drug discovery for spinal muscular atrophy: a story of small molecules and antisense oligonucleotides.
    Torroba B; Macabuag N; Haisma EM; O'Neill A; Herva ME; Redis RS; Templin MV; Black LE; Fischer DF
    Expert Opin Drug Discov; 2023 Feb; 18(2):181-192. PubMed ID: 36408582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidative Stress Triggers Body-Wide Skipping of Multiple Exons of the Spinal Muscular Atrophy Gene.
    Seo J; Singh NN; Ottesen EW; Sivanesan S; Shishimorova M; Singh RN
    PLoS One; 2016; 11(4):e0154390. PubMed ID: 27111068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.
    Singh NN; Lee BM; DiDonato CJ; Singh RN
    Future Med Chem; 2015; 7(13):1793-808. PubMed ID: 26381381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of spinal muscular atrophy via correction of the SMN2 splicing defect by Brucea javanica (L.) Merr. extract and Bruceine D.
    Baek J; Jeong H; Ham Y; Jo YH; Choi M; Kang M; Son B; Choi S; Ryu HW; Kim J; Shen H; Sydara K; Lee SW; Kim SY; Han SB; Oh SR; Cho S
    Phytomedicine; 2019 Dec; 65():153089. PubMed ID: 31563042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy.
    Zhao X; Feng Z; Ling KK; Mollin A; Sheedy J; Yeh S; Petruska J; Narasimhan J; Dakka A; Welch EM; Karp G; Chen KS; Metzger F; Ratni H; Lotti F; Tisdale S; Naryshkin NA; Pellizzoni L; Paushkin S; Ko CP; Weetall M
    Hum Mol Genet; 2016 May; 25(10):1885-1899. PubMed ID: 26931466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.